Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Depomed Inc (DEPO) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,226,080
  • Shares Outstanding, K 61,510
  • Annual Sales, $ 342,740 K
  • Annual Income, $ -75,740 K
  • 36-Month Beta 1.40
  • Price/Sales 3.60
  • Price/Book 4.24

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.27 +10.56%
on 11/22/16
21.56 -6.31%
on 11/15/16
+0.44 (+2.23%)
since 11/09/16
3-Month
17.42 +15.96%
on 11/08/16
27.02 -25.24%
on 09/30/16
-1.75 (-7.97%)
since 09/09/16
52-Week
12.25 +64.90%
on 03/24/16
27.02 -25.24%
on 09/30/16
+1.04 (+5.43%)
since 12/09/15

Most Recent Stories

More News
Depomed to Present at the Annual Piper Jaffray Healthcare Conference

Depomed, Inc. (NASDAQ:DEPO) today announced that it will participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare Conference scheduled for 2:00 pm ET (11:00 am PT) on Tuesday, November...

Blog Coverage Cumberland Pharma Bags Exclusive Rights for Europe Based Nordic Group Injectable Methotrexate Product Line for the US Market

Upcoming AWS Coverage on Depomed Post-Earnings Results

Upgrade Alert for Depomed (DEPO)

Depomed (NASDAQ:DEPO) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $19.76 on volume of 4.7 million shares, above average daily volume of 2.2 million. DepoMed, Inc....

Downgrade Alert for Depomed (DEPO)

Depomed (NASDAQ:DEPO) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $19.01 on volume of 10.9 million shares, above average daily volume of 2.2 million. Depomed (NASDAQ:DEPO)...

Hertz and CVS plunge; SeaWorld, Priceline gain

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:

Look for Shares of Depomed to Potentially Rebound after Yesterday's 16.97% Sell Off

Depomed (NASDAQ:DEPO) traded in a range yesterday that spanned from a low of $17.42 to a high of $19.85. Yesterday, the shares fell 17.0%, which took the trading range below the 3-day low of $21.45 on...

Depomed Reports Third Quarter 2016 Financial Results

- Third Quarter Revenues of $111 million -

Drug Makers Stocks on Investors' Radar -- Amarin, Depomed, DURECT, and Biodel

Last Friday, benchmark US indices extended their bearish trend as the NASDAQ Composite ended the trading session down 0.24%; the Dow Jones Industrial Average edged 0.24% lower; and the S&P 500 closed down...

Blog Coverage MEI Pharma and Helsinn Group Announced Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia

Upcoming AWS Coverage on Depomed Post-Earnings Results

Depomed Announces New CAMBIA(R) Formulation

Depomed Inc. (NASDAQ:DEPO) today announced the introduction of a new formulation of CAMBIA (diclofenac potassium) for oral solution, that contains the sweetener sucralose, replacing the sweeteners saccharin...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once- daily administration and reduced side effects,...

See More

Support & Resistance

2nd Resistance Point 20.72
1st Resistance Point 20.46
Last Price 20.20
1st Support Level 19.97
2nd Support Level 19.74

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.